Anzeige
Mehr »
Login
Freitag, 26.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Geheimtipp: Rasanter Aufstieg, Branchenrevolution und Jahresumsatz von 50 Mio. $
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
724 Leser
Artikel bewerten:
(2)

Cyient Enters into a Manufacturing Collaboration with Agappe to Bring World-Class Diagnostic Capabilities to Rural India

HYDERABAD, India, Sept. 9, 2020 /PRNewswire/ -- Cyient, a global engineering and digital technology solutions company, today announced that it has entered into a manufacturing partnership with Agappe to bring to market Count X. The Mispa Count X is an indigenously designed and developed three-part hematology analyzer by Agappe, that will make India self-reliant in hematology and enable the setup of well-equipped labs in remote and rural locations across India. Cyient will manufacture certain key components of Mispa Count X at its ISO 13485-certified, state-of-art manufacturing facilities in India.

Maximizing the ROI of Your IoT Initiatives and Connected Assets

Rajendra Velagapudi, Senior Vice President and CEO, Cyient DLM, commented, "We are proud to support the vision of an Atmanirbhar Bharat (self-reliant India) in the healthcare sector. It is a matter of immense pride that with Agappe's new hematology product, even rural India and other remote locations of the country will have access to the best of diagnostic capabilities."

Cyient's world-class facilities, project management, sourcing, supply chain management, production processes, buoyed by investments in the latest technologies as well as expertise in the delivery of quality products, make it a preferred manufacturing partner for aerospace, defense, medical, and industrial customers globally.

Dr. Satheesh Kumar CS, Senior Vice President, Agappe, said, "This partnership will enable Agappe to deliver high-quality, affordable, 100% made-in-India products by taking advantage of Cyient's ultra-modern manufacturing facilities to manufacture some of the key components of Mispa Count X so as to reduce time-to-market and lower operating costs. We are eager to get started with full-scale production in our manufacturing facility at Cochin and fulfill customer orders on time."

About Cyient:
Cyient (Estd: 1991, NSE: CYIENT) is a global engineering and digital technology solutions company. As a Design, Build, and Maintain partner for leading organizations worldwide, Cyient takes solution ownership across the value chain to help customers focus on their core, innovate, and stay ahead of the curve. The company leverages digital technologies, advanced analytics capabilities, domain knowledge, and technical expertise to solve complex business problems.

Cyient partners with customers to operate as part of their extended team in ways that best suit their organization's culture and requirements. Cyient's industry focus includes aerospace and defense, healthcare, telecommunications, rail transportation, semiconductor, geospatial, industrial, and energy.

For more information, please visit www.cyient.com

Follow news about the company at @Cyient

Contact Details
Perfect Relations
Vishal Thapa
Mobile: +91 9701834446
Email: vthapa@perfectrelations.com

Logo - https://mma.prnewswire.com/media/289359/cyient_logo.jpg

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2020 PR Newswire
Diesen Artikel auf Deutsch lesen
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.